Stocks and Investing Stocks and Investing
Tue, May 7, 2024

Sumant Kulkarni Maintained (STOK) at Strong Buy with Decreased Target to $20 on, May 7th, 2024


Published on 2024-10-28 11:02:33 - WOPRAI, Sumant Kulkarni
  Print publication without navigation


Sumant Kulkarni of Canaccord Genuity, Maintained "Stoke Therapeutics, Inc." (STOK) at Strong Buy with Decreased Target from $21 to $20 on, May 7th, 2024.

Sumant has made no other calls on STOK in the last 4 months.



There are 5 other peers that have a rating on STOK. Out of the 5 peers that are also analyzing STOK, 1 agrees with Sumant's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Jessica Fye of "JP Morgan" Maintained at Hold with Increased Target to $13 on, Tuesday, March 26th, 2024


These are the ratings of the 4 analyists that currently disagree with Sumant


  • Joseph Stringer of "Needham" Reiterated at Strong Buy and Held Target at $22 on, Monday, May 6th, 2024
  • Charles Duncan of "Cantor Fitzgerald" Reiterated at Buy on, Thursday, April 4th, 2024
  • Laura Chico of "Wedbush" Maintained at Buy with Increased Target to $17 on, Tuesday, March 26th, 2024
  • Yaron Werber of "TD Cowen" Upgraded from Hold to Strong Buy on, Tuesday, March 26th, 2024
Contributing Sources